TTD | Drug: D0N2QW

Drug General Information
Drug ID	D0N2QW
Former ID	DIB015717
Drug Name	Patritumab
Drug Type	Antibody
Indication	Non-small cell lung cancer [ICD10:C33-C34]		Phase 1	[524459]
Company	Daiichi sankyo
Target and Pathway
Target(s)	Receptor protein-tyrosine kinase erbB-3	Target Info		[532632]
KEGG Pathway	ErbB signaling pathway
	Calcium signaling pathway
	Endocytosis
	Proteoglycans in cancer
	MicroRNAs in cancer
NetPath Pathway	TNFalpha Signaling Pathway
PANTHER Pathway	Cadherin signaling pathway
PANTHER Pathway	EGF receptor signaling pathway
Pathway Interaction Database	ErbB2/ErbB3 signaling events
	ErbB receptor signaling network
	a6b1 and a6b4 Integrin signaling
WikiPathways	ErbB Signaling Pathway
	Apoptosis-related network due to altered Notch3 in ovarian cancer
	Signaling Pathways in Glioblastoma
	miR-targeted genes in muscle cell - TarBase
	Heart Development
References
Ref 524459	ClinicalTrials.gov (NCT01957280) Study to Assess Pharmacokinetics, Immunogenicity and Safety/Tolerability of Patritumab (U3-1287). U.S. National Institutes of Health.
Ref 532632	Phase 1 and dose-finding study of patritumab (U3-1287), a human monoclonal antibody targeting HER3, in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol. 2014 Mar;73(3):511-6.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.

Drug Information